PMID- 20093977
OWN - NLM
STAT- MEDLINE
DCOM- 20100527
LR  - 20211203
IS  - 1556-1380 (Electronic)
IS  - 1556-0864 (Linking)
VI  - 5
IP  - 3
DP  - 2010 Mar
TI  - Overexpression of the mammalian target of rapamycin: a novel biomarker for poor 
      survival in resected early stage non-small cell lung cancer.
PG  - 314-9
LID - 10.1097/JTO.0b013e3181ce6604 [doi]
AB  - INTRODUCTION: The best hope of cure for patients with non-small cell lung cancer 
      (NSCLC) is surgical resection. However, even in stage IA patients, 30% die within 
      5 years. Further improvements in survival require a biomarker(s), which defines 
      the subset of these patients destined to do badly so that they could be targeted 
      for additional therapies. Here, we investigate whether the immunohistochemical 
      expression of a key kinase implicated in lung cancer biology, the mammalian 
      target of rapamycin (mTOR) can predict survival outcome in patients with early 
      stage resected NSCLC. MATERIALS AND METHODS: One hundred thirty-four patients 
      with resected early stage (IA-IIB) NSCLC were pathologically reviewed centrally 
      before staining for mTOR. Multiple variables including age, sex, stage, 
      angioinvasion, lymph node status, and mTOR staining were assessed by univariate 
      and multivariate analyses. RESULTS: Stage (p = 0.044), lymph node status (p = 
      0.049), angioinvasion (p = 0.017), and mTOR staining (p = 0.007) were significant 
      univariate predictors of poor survival. However, only angioinvasion (p = 0.016) 
      and mTOR staining (p = 0.046) remained significant after multivariate analysis. 
      Moreover, mTOR staining was the only variable to predict poor outcome in patients 
      who either had negative lymph nodes (p = 0.016) or were stage IA (p = 0.0016). 
      CONCLUSIONS: The mTOR staining provides a new biomarker for poor outcome in early 
      stage NSCLC and could enable resected stage IA patients to be selected for novel 
      therapies possibly with an mTOR inhibitor.
FAU - Dhillon, Tony
AU  - Dhillon T
AD  - CR-UK Laboratories, Imperial College London, Hammersmith Hospitals campus, 
      London, United Kingdom.
FAU - Mauri, Francesco A
AU  - Mauri FA
FAU - Bellezza, Guido
AU  - Bellezza G
FAU - Cagini, Lucio
AU  - Cagini L
FAU - Barbareschi, Mattia
AU  - Barbareschi M
FAU - North, Bernard V
AU  - North BV
FAU - Seckl, Michael J
AU  - Seckl MJ
LA  - eng
GR  - Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Thorac Oncol
JT  - Journal of thoracic oncology : official publication of the International 
      Association for the Study of Lung Cancer
JID - 101274235
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Adenocarcinoma/metabolism/mortality/pathology
MH  - Adenocarcinoma, Bronchiolo-Alveolar/metabolism/mortality/pathology
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Large Cell/metabolism/mortality/pathology
MH  - Carcinoma, Neuroendocrine/metabolism/mortality/pathology
MH  - Carcinoma, Non-Small-Cell Lung/metabolism/*mortality/pathology
MH  - Carcinoma, Squamous Cell/metabolism/mortality/pathology
MH  - Female
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Intracellular Signaling Peptides and Proteins/*metabolism
MH  - Lung Neoplasms/metabolism/*mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Invasiveness
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Protein Serine-Threonine Kinases/*metabolism
MH  - Survival Rate
MH  - TOR Serine-Threonine Kinases
MH  - Tissue Array Analysis
EDAT- 2010/01/23 06:00
MHDA- 2010/05/28 06:00
CRDT- 2010/01/23 06:00
PHST- 2010/01/23 06:00 [entrez]
PHST- 2010/01/23 06:00 [pubmed]
PHST- 2010/05/28 06:00 [medline]
AID - S1556-0864(15)32302-9 [pii]
AID - 10.1097/JTO.0b013e3181ce6604 [doi]
PST - ppublish
SO  - J Thorac Oncol. 2010 Mar;5(3):314-9. doi: 10.1097/JTO.0b013e3181ce6604.